AI-Powered test aims to predict best cancer treatment for each patient

NCT ID NCT06929338

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study tests a new platform called xDRIVE that combines drug sensitivity testing and AI to predict which treatments will work best for people with advanced colorectal cancer. The platform will not provide treatment itself but will give doctors a recommendation. The goal is to see if xDRIVE can accurately predict treatment response in at least 80% of the 30 participants. If it works, this could help personalize cancer therapy and avoid ineffective treatments.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
xDRIVE functional precision medicine platform (diagnostic test)
What this could lead to
If successful, this platform could help doctors choose the most effective therapy for each patient, improving outcomes and avoiding ineffective treatments.
What could go wrong
This is a small, early feasibility study with only 30 participants. The platform may not reach the target accuracy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLON ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.